Sugi Predict

Sugi Predict / Compounds / SCHEMBL304803

SCHEMBL304803

SCHEMBL304803

CC(C)(C)OC(=O)N1CCO[C@H](CO)C1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ PDK1 Q15118 5/20 0.50
▸ NR1H2 P55055 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ HPGD P15428 1/20 0.42
▸ MAPT P10636 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ EPHA2 P29317 3/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ ERBB2 P04626 1/20 0.39
▸ EPHB4 P54760 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL304804 1.00 USP2 (0.53) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL8904969 1.00 USP2 (0.53) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL553919 1.00 USP2 (0.53) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL306580 0.91 PDK1 (0.52) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL305277 0.91 PDK1 (0.52) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL305278 0.91 PDK1 (0.52) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL29864929 0.91 RECQL (0.49) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL30987096 0.90 HPGD (0.49) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL1655537 0.88 USP2 (0.50) USP2SMN1; SMN2PDK1NR1H2RECQL
SCHEMBL31040994 0.88 USP2 (0.50) USP2SMN1; SMN2PDK1NR1H2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 639 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746969-A1 HETEROCYCLIC PAD4 INHIBITORS Bristol-Myers Squibb Company (US) 2026-05-27 — — EP disclosed
EP-4743465-A1 BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-20 — — EP disclosed
US-12624043-B2 Compositions useful for treating disorders related to kit BLUEPRINT MEDICINES CORPORATION (US) 2026-05-12 — — US disclosed
EP-4735114-A1 SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES Masarykova Univerzita (CZ) 2026-05-06 — — EP disclosed
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20260085066-A1 LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2026-03-26 — — US disclosed
EP-4711365-A1 THIAZOLE DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2026-03-18 — — EP disclosed
EP-4695259-A1 TRICYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2026-02-18 — — EP disclosed
EP-3959211-B1 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS BAYER AG (DE) 2026-02-18 — — EP disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-20040142931-A1 C-6 modified indazolylpyrrolotriazines BRISTOL-MYERS SQUIBB COMPANY 2004-07-22 — — US disclosed
US-20040072832-A1 Novel inhibitors of kinases BRISTOL-MYERS SQUIBB COMPANY 2004-04-15 — — US disclosed
WO-2004009784-A2 NOVEL INHIBITORS OF KINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-29 — — WO disclosed
US-20030186983-A1 C-5 Modified indazolylpyrrolotriazines BRISTOL-MYERS SQUIBB COMPANY 2003-10-02 — — US disclosed
WO-2003078395-A1 PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2003-09-25 — — WO disclosed
US-20030114668-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-19 — — US disclosed
WO-2003042172-A2 C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-05-22 — — WO disclosed
US-5698685-A Morpholino-subunit combinatorial library and method ANTIVIRALS INC. (US) 1997-12-16 — — US disclosed
US-5506337-A Morpholino-subunit combinatorial library and method ANTIVIRALS INC. (US) 1996-04-09 — — US disclosed
WO-1995031459-A1 MORPHOLINO-SUBUNIT COMBINATORIAL LIBRARY AND METHOD ANTIVIRALS INC. (US) 1995-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 USP2 740/4885SMN1; SMN2 1781/4885PDK1 590/4885
US-12624043-B2 Compositions useful for treating disorders related to kit KIT, RET, SLC26A4 USP2 2177/4885SMN1; SMN2 549/4885PDK1 1725/4885
US-20030186983-A1 C-5 Modified indazolylpyrrolotriazines ERBB2, ERBB4, EGFR USP2 4320/4885SMN1; SMN2 4592/4885PDK1 889/4885
US-20040072832-A1 Novel inhibitors of kinases FGFR1, FLT1, FGFR2 USP2 4481/4885SMN1; SMN2 4183/4885PDK1 217/4885
US-20030114668-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS TACR1, NPSR1, SSTR2 USP2 3514/4885SMN1; SMN2 4534/4885PDK1 1848/4885
US-20040142931-A1 C-6 modified indazolylpyrrolotriazines ERBB2, ERBB4, EGFR USP2 4320/4885SMN1; SMN2 4567/4885PDK1 907/4885
US-20260085066-A1 LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, PARK7, NEDD4 USP2 83/4885SMN1; SMN2 491/4885PDK1 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.